CLGN vs INBS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CLGN shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
The company exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health. While revenue growth is strong at 47.6% and the balance sheet shows low debt (D/E 0.18), these are overshadowed by an operating margin of -290.89% and a total collapse in share price, which is currently at its 52-week low. The stock is in a clear technical downtrend with a 1-year return of -79.8%, suggesting a lack of investor confidence despite the low Price-to-Book ratio.
Compare Another Pair
Related Comparisons
CLGN vs INBS: Head-to-Head Comparison
This page compares CollPlant Biotechnologies Ltd. (CLGN) and Intelligent Bio Solutions Inc. (INBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.